Sun Pharma Secures MFN Pricing Agreement
Sun Pharmaceutical Industries has formally agreed to apply Most Favoured Nation (MFN) pricing to state Medicaid programs across the United States. This significant commitment, announced at a White House signing ceremony on September 1, 2026, also extends the MFN mechanism to all future innovative medicine launches by the Indian drugmaker. Crucially, the agreement provides Sun Pharma with a reprieve from potential Section 232 tariffs on its innovative pharmaceutical products for more than two years, solidifying its position in the American market.
Strategic Shift Towards Innovative Medicines
This development comes at a pivotal time for Sun Pharma as it strategically shifts its US business focus beyond generic drugs towards higher-value specialty and innovative medicines. The United States represents Sun Pharma's largest market for innovative products, contributing approximately 27% of its global revenue, making its long-term growth plans intrinsically linked to its American operations.
Rick Ascroft, North America CEO of Sun Pharma, who attended the White House ceremony, emphasized the company's commitment. "The United States is a key area of investment and expansion for Sun Pharma across clinical development, sales and marketing, and both API and finished products manufacturing," Ascroft stated, expressing pride in providing essential medicines to millions of American patients.
Strengthening US Supply Chains
Beyond pricing, the agreement includes a commitment to bolster US pharmaceutical supply chains. Sun Pharma will contribute 71.4 tonnes of clindamycin and 6.75 tonnes of doxycycline – both critical antibiotics – to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). This initiative aims to reduce reliance on foreign sources and guarantee adequate supplies of key medicines during emergencies. Furthermore, the White House noted that the nine pharmaceutical manufacturers involved in these latest agreements collectively committed to invest at least $19.6 billion in US manufacturing in the near term.
Expanding US Market Presence
Sun Pharma's US presence, initially built on generics, has expanded significantly into innovative and specialty medicines. The company currently holds the second position by prescriptions in US dermatology and maintains strong businesses in immunology, cutaneous oncology, and ophthalmology, alongside its consumer health and generics operations.
The MFN agreement aligns with Sun Pharma's broader strategy to deepen its commitment to the American market, exemplified by its earlier acquisition of Organon & Co. at an enterprise value of $11.75 billion. This transaction underscores Sun Pharma's continued investment and efforts to expand its reach among American patients, healthcare providers, and communities, leveraging its global innovative medicines portfolio across dermatology, ophthalmology, and onco-dermatology, which accounts for about 22% of the company's total sales.